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We investigated whether theC9orf72 repeat expansion is associated with specific clinical
features, comorbidities, and prognosis in patients with amyotrophic lateral sclerosis
(ALS). A cohort of 1417 ALS patients, diagnosed between January 1, 2009 and
December 31, 2013 by 13 Italian ALS Referral Centers, was screened for the C9orf72
repeat expansion, and the analyses were performed comparing patients carrying this
expansion (ALS-C9Pos) to those negative for this and other explored ALS-related
mutations (ALS without genetic mutations, ALSwoGM). Compared to the ALSwoGM
group, ALS-C9Pos patients (n = 84) were younger at disease onset, at the first clinical
observation and at diagnosis (p< 0.001). After correcting for these differences, we found
that ALS-C9Pos patients had higher odds of bulbar onset, diagnosis of frontotemporal
dementia (FTD) and family history of ALS, FTD, and Alzheimer’s disease and had lower
odds of spinal onset, non-invasive ventilation, hypertension and psychiatric diseases than
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ALSwoGM patients. Among these variables, those related to shorter survival time were:
bulbar onset, presence of FTD, hypertension, psychiatric disease, and family history of
ALS (p < 0.05). Cox proportional hazards regression multivariate analysis suggested that
carrying the C9orf72 repeat expansion was an independent factor negatively impacting
on survival time in men (HR 1.58, 95% CI 1.07–2.33, p = 0.021), but not in women
(p > 0.05) as well as in the whole sample (p > 0.05). When compared to ALSwoGM,
ALS-C9Pos showed an earlier disease onset, no significant diagnostic delay and a higher
odds of bulbar onset, FTD and family history of ALS and dementia. Moreover, male sex
drove the negative effect of expanded variant on survival, confirming the hypothesis that
sex is likely to be a crucial factor in the biology of C9orf72-related disease.
Keywords: amyotrophic lateral sclerosis, C9orf72 expansion, gender, comorbidity, survival
INTRODUCTION
The pathological expansion of a hexanucleotide repeat in the
C9orf72 gene is the most common genetic mutation identified
in patients with amyotrophic lateral sclerosis (ALS), reported
in 40–50% of patients with familial ALS and 5–10% of patients
with sporadic ALS (DeJesus-Hernandez et al., 2011; Renton et al.,
2011; Majounie et al., 2012). Patients carrying the expansion
(ALS-C9Pos) have been described as phenotypically different
from non-mutated patients in that most cohorts of ALS-C9Pos
patients exhibited, at variable extent, higher prevalence of bulbar
onset, earlier age at onset and reduced survival with higher
incidence of comorbid frontotemporal dementia (FTD) and/or
family history of dementia or ALS (Byrne et al., 2012, 2013;
Chiò et al., 2012; Cooper-Knock et al., 2012; Majounie et al.,
2012; Sabatelli et al., 2012; Irwin et al., 2013; Umoh et al., 2016;
Hardiman et al., 2017). Although the C9orf72 repeat expansion
has been revealed a relevant negative prognostic factor in survival
analyses (Byrne et al., 2012, 2013; Chiò et al., 2012; Sabatelli
et al., 2012; Irwin et al., 2013; Umoh et al., 2016), the potential
associations between this variant and demographic and clinical
features have not still completely elucidated. Among the most
robust evidence on prognostic char (Rooney et al., 2017) a
previously unrecognized interaction between the C9orf72 repeat
expansion and sex (Rooney et al., 2017). Nevertheless, the same
authors suggested to further evaluate the role of other clinical
variables, such as the presence of cognitive changes, in the
abovementioned interaction effect. Additionally, Miltenberger-
Miltenyi et al. (2018) found that the C9orf72 expansion was
associated with FTD, shorter survival and faster % Forced Vital
Capacity (FVC) decline in ALS, but not with a faster rate of
functional decay.
In this large multicenter cohort we aimed at: (i) examining
the potential associations between C9orf72 repeat expansion and
phenotype, site of onset, family history, therapy, and others
comorbidities; (ii) exploring if ALS patients carrying C9orf72
repeat expansion differed from patients without genetic mutation
in the survival profile, both in the whole sample and stratified
by sex. We expected to identify potential novel associations
between C9orf72 repeat expansion and a number of demographic
and clinical features, focusing on the effect of sex on the
survival profile.
MATERIALS AND METHODS
Patient Data Collection
This study has been designed and performed in 13 ALS Italian
referral centers, located in 10 Italian Regions: ALS Centers of
Turin, Padua, Genoa, Naples, Modena, Lecce, Rome, NEMO
Clinical Centers in Milan, and Messina, ALS Centers of ICS
Maugeri in Milan and Mistretta, ALS Centers at San Raffaele
Institute, and IRCCS Istituto Auxologico Italiano inMilan (Calvo
et al., 2017; Trojsi et al., 2017b; Mandrioli et al., 2018a). We
included 1417 patients, diagnosed with definite or clinical and
laboratory-supported probable ALS, according to the Revised
El Escorial Criteria (Brooks et al., 2000), from January 1st,
2009 to December 31st, 2013, in whom genetic data were
available (Figure 1).
Data have been recorded into an electronic database available
to all involved centers. According to previously used selection
methods (Umoh et al., 2016), all patients followed at the involved
ALS referral centers were consecutively asked to donate DNA for
research purposes, and the only criteria for inclusion were the
diagnosis of ALS and the consent to donate blood for genetic
screening. Caring neurologists collected a detailed phenotypic
profile for each ALS patient, including the following information:
among demographic data, sex, age at onset, at clinical observation
and at diagnosis; among clinical data, site, and time of onset,
clinical phenotype [classic, bulbar, predominant upper motor
neuron (UMN-p), flail arm, flail leg, and respiratory ALS] (Chiò
et al., 2011), presence of concomitant dementia and family
history of ALS, FTD or other neurodegenerative diseases (i.e.,
Parkinson’s and Alzheimer’s disease), metabolic (i.e., diabetes),
oncologic, cardiovascular (i.e., hypertension, atrial fibrillation,
and heart failure), auto-immune, hematological, gastroenteric,
and psychiatric diseases. The genetic analysis included screening
for SOD1, FUS, TARDBP, and C9orf72 status (normal or
expanded), four genes accounting for up to 70% of all cases of
familial ALS (Hardiman et al., 2017). When mutations of these
genes or C9orf72 expansion were not revealed and in presence
of family history of ALS and/or FTD, mutations of ALS2, ANG,
DYT11, OPTN, and PGRN were also explored. C9orf72 status
was determined by repeat primed PCR as described previously
(with individual laboratory-based validation and quality control
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FIGURE 1 | Flow chart representing the studied cohort from 13 ALS Italian referral centers, in which genetic data were available.
by Southern blot analyses) (DeJesus-Hernandez et al., 2011;
Renton et al., 2011; Byrne et al., 2012, 2013; Chiò et al., 2012;
Cooper-Knock et al., 2012; Majounie et al., 2012; Sabatelli et al.,
2012; Irwin et al., 2013; Umoh et al., 2016). Among outcome
information, dates of percutaneous endoscopic gastrostomy
(PEG), non-invasive ventilation (NIV) and tracheotomy/death
were also collected.
This study was approved by the Ethical Committees of
the participating ALS centers and conducted according to the
principles expressed in the Declaration of Helsinki. Patient or
family written consent was obtained from each participant.
Statistical Analysis
Descriptive statistics are reported as count and percentage for
categorical variables (i.e., sex) ormean and standard deviation for
continuous variables (i.e., age at onset, age at clinical observation,
age at diagnosis and diagnostic delay).
The comparisons between ALS-C9Pos and ALS patients
without genetic mutations (ALSwoGM) were performed using
one-way analysis of variance (ANOVA), and Pearson chi-square
test (χ2), when appropriate.
Logistic regression analyses (hierarchical method) were used
for measuring the association between the presence of C9orf72
expansion and clinical phenotype (i.e., classic, bulbar, flail arm,
flail leg, and UMN-p), site of onset (i.e., spinal and bulbar),
therapeutic interventions (i.e., NIV, PEG, tracheostomy, and
riluzole), other diseases (i.e., FTD, diabetes, hypertension, heart
disease, cancer, autoimmune, hematological, gastroenteric, and
psychiatric), and family history (i.e., ALS, FTD, and Parkinson’s
and Alzheimer’s disease). All logistic regression models were
adjusted for baseline demographic and clinical differences
between ALS-C9Pos and ALSwoGM, and the results were
presented as adjusted odds ratio (OR). Kaplan-Meier univariate
analysis was used to determine the effect of C9orf72 repeat
expansion on the survival time for the whole sample as well
as for the men and the women. Moreover, the univariate effect
on survival time of the variables associated to the presence of
C9orf72 repeat expansion was explored by Kaplan-Meier analysis
for categorical variables (using the log-rank test) and by Cox
proportional hazards analysis for continuous variables (using
hazard ratios or HR, and 95% confidence interval or 95% CI).
Finally, Cox proportional hazards regression multivariate
analysis (Forward Conditional method) was performed entering
the variables associated with the survival time in univariate
analyses in order to explore the effect of the C9orf72 repeat
expansion on survival time in a multivariate model. These
analyses were performed in the whole sample and, then,
stratifying by sex. Survival time was defined as time from
symptom onset to time of death/tracheotomy. Patients who were
alive at time of analysis were censored.
Statistical analyses were performed using IBM Statistical
Package for Social Science (SPSS) version 20, with p-value< 0.05.
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TABLE 1 | Descriptive statistics of amyotrophic lateral sclerosis patients with
pathogenic C9orf72 expansion (ALS-C9Pos) and without genetic mutations
(ALSwoGM).
ALS-C9Pos
(n = 84)
ALSwoGM
(n = 1240)
F/χ2 p
Sex, n (%)
Male 47 (54%) 681 (55%) 0.03 0.854
Female 37 (46%) 559 (45%)
Mean age at onset, years
(SD)
58.49 (9.55) 63.41 (11.6) 14.44 <0.001
Mean age at clinical
observation, years (SD)
64.36 (9.78) 69.82 (11.47) 18.10 <0.001
Mean age at diagnosis,
years (SD)
59.47 (9.55) 64.69 (11.44) 16.69 <0.001
Diagnostic delay, months
(SD)
11.73 (8.58) 15.35 (21.85) 2.28 0.131
ALS-C9Pos, amyotrophic lateral sclerosis with pathogenic C9orf72 expansion;
ALSwoGM, amyotrophic lateral sclerosis without genetic mutations; significant differences
are signed in bold; SD, standard deviation.
RESULTS
The C9orf72 repeat expansion was identified in 84 cases
(Figure 1). ALSwoGM were 1240, excluding 93 ALS patients
carrying other genetic mutations (Figure 1).
Comparing ALS-C9Pos to ALSwoGM patients, there were
significant differences in age at onset, age at clinical observation,
and age at diagnosis (Table 1).
After having adjusted for demographic and clinical
differences, logistic regression analyses showed that pathogenic
C9orf72 expansion was associated with higher OR of bulbar
onset, FTD diagnosis, and family history of ALS, FTD, and
Alzheimer’s disease. In addition, the C9orf72 expansion was
associated with lower OR of spinal onset, NIV, hypertension,
and psychiatric diseases (Table 2). Noteworthy, no ALS patients
with pathogenic C9orf72 expansion had respiratory phenotype
or respiratory onset.
Kaplan-Meier analysis showed that ALS-C9Pos patients had
shorter survival time than ALSwoGM patients (Figure 2). When
the overall sample was stratified according to sex, this pattern
of results was confirmed only for men (Figure 3). However,
a preliminary Kaplan-Meier analysis did not show significant
differences in the survival time comparing men to women for the
overall sample, regardless of the stratification due to the presence
of C9orf72 repeat expansion (Supplemental Figure 1). Among
the variables associated with the presence of C9orf72 expansion,
those related to shorter survival time on univariate analyses
included the following: (1) higher age at onset (HR 1.04, 95% CI
1.03–1.04, p < 0.0001); (2) higher age at clinical observation (HR
1.03, 95% CI 1.02–1.04, p < 0.0001); (3) higher age at diagnosis
(HR 1.03, 95% CI 1.02–1.04, p < 0.0001); (4) site of onset, with
worse outcome for bulbar onset (log-rank test, p < 0.0001);
(5) the presence of FTD (log-rank test, p < 0.0001); (6)
hypertension (log-rank test, p < 0.0001); (7) psychiatric diseases
(log-rank test, p = 0.047); (8) family history of ALS (log-rank
test, p= 0.015).
TABLE 2 | Relationship between pathogenic C9orf72 expansion and phenotype,
site onset, family history, therapy, and others comorbidities in patients with
amyotrophic lateral sclerosis.
ALS-C9Pos ALSwoGM p OR 95%CI
n (%) n (%)
Classic phenotype
Yes 53 (63%) 633 (51%) 0.132 1.42 [0.89, 2.26]
No 31 (37%) 607 (49%)
Bulbar phenotype
Yes 16 (19%) 224 (18%) 0.434 1.25 [0.71, 2.24]
No 68 (81%) 1016 (82%)
Flail arm phenotype
Yes 1 (1%) 79 (6%) 0.102 0.19 [0.02, 1.39]
No 83 (99%) 1161 (94%)
Flail leg phenotype
Yes 1 (1%) 76 (6%) 0.113 0.20 [0.02, 1.46]
No 83 (99%) 1164 (94%)
Umn phenotype
Yes 5 (6%) 108 (9%) 0.375 0.65 [0.25, 1.66]
No 79 (94%) 1132 (91%)
Spinal onset
Yes 51 (61%) 881 (71%) 0.009 0.53 [0.33, 0.85]
No 33 (39%) 358 (29%)
Bulbar onset
Yes 32 (38%) 346 (28%) 0.012 1.83 [1.14, 2.93]
No 52 (62%) 893 (72%)
NIV
Yes 26 (31%) 580 (47%) 0.015 0.55 [0.33, 0.89]
No 58 (69%) 660 (53%)
PEG
Yes 31 (37%) 415 (34%) 0.377 1.23 [0.77, 1.98]
No 53 (63%) 825 (66%)
Tracheostomy
Yes 17 (20%) 203 (16%) 0.386 1.28 [0.73, 2.24]
No 67 (80%) 1037 (84%)
Riluzole
Yes 74 (88%) 1043 (84%) 0.591 1.20 [0.61, 2.4]
No 10 (12%) 197 (16%)
FTD
Yes 22 (26%) 93 (7%) <0.001 5.41 [3.10, 9.45]
No 62 (74%) 1147 (93%)
Diabetes
Yes 3 (4%) 116 (9%) 0.143 0.41 [0.13, 1.34]
No 81 (96%) 1124 (91%)
Hypertension
Yes 19 (23%) 561 (45%) 0.004 0.45 [0.26, 0.78]
No 65 (77%) 679 (55%)
Heart Diseases
Yes 5 (6%) 203 (16%) 0.080 0.43 [0.17, 1.10]
No 79 (94%) 1037 (84%)
Cancer
Yes 4 (5%) 141 (11%) 0.119 0.44 [0.15, 1.23]
No 80 (95%) 1099 (89%)
(Continued)
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TABLE 2 | Continued
ALS-C9Pos ALSwoGM p OR 95%CI
n (%) n (%)
Autoimmune diseases
Yes 6 (7%) 90 (7%) 0.979 0.99 [0.41, 2.35]
No 78 (93%) 1150 (93%)
Hematological diseases
Yes 1 (1%) 48 (4%) 0.332 0.37 [0.05, 2.74]
No 83 (99%) 1192 (96%)
Gastroenteric diseases
Yes 7 (8%) 197 (16%) 0.070 0.48 [0.21, 1.06]
No 77 (92%) 1043 (84%)
Psychiatric diseases
Yes 4 (5%) 143 (12%) 0.043 0.35 [0.12, 0.96]
No 80 (95%) 1097 (88%)
Family history of ALS
Yes 38 (45%) 51 (4%) <0.001 17.26 [10.25, 29.05]
No 46 (55%) 1189 (96%)
Family history of PD
Yes 3 (4%) 49 (4%) 0.640 0.75 [0.23, 2.49]
No 81 (96%) 1191 (96%)
Family history of FTD
Yes 15 (18%) 14 (1%) <0.001 16.23 [7.39, 35.62]
No 69 (82%) 1226 (99%)
Family history of AD
Yes 18 (21%) 100 (8%) 0.001 2.70 [1.52, 4.79]
No 66 (79%) 1140 (92%)
ALS, amyotrophic lateral sclerosis; ALS-C9Pos, amyotrophic lateral sclerosis with
pathogenic C9orf72 expansion; ALSwoGM, amyotrophic lateral sclerosis without genetic
mutations; adjOR, adjusted odds ratio; AD, Alzheimer’s disease; FTD, frontotemporal
dementia; NIV, non-invasive ventilation; PD, Parkinson’s disease; PEG, percutaneous
endoscopic gastrostomy; significant associations are signed in bold.
Cox proportional hazards regression multivariate analysis
showed that shorter survival time was associated with the
presence of C9orf72 expansion in men (HR 1.58, 95% CI 1.07–
2.33, p = 0.021), but not in women (p > 0.05) as well as in
the whole sample (p > 0.05) (Table 3; Figure 4; see also the
Supplemental Table 1 for variables that were not included in the
equation for each step of the Cox proportional hazards regression
multivariate analysis).
DISCUSSION
Patients with ALS carrying the C9orf72 repeat expansion have
been shown to exhibit remarkable clinical and pathological
features suggesting that this hexanucleotide expansion identifies
a distinct population of patients, with significant implications
on therapeutic interventions design and screening for inclusion
in clinical trials. In our multicenter analysis, performed on data
from 1417 patients, we compared demographic and clinical
features of a population of ALS-C9Pos patients to those of a
cohort of ALSwoGM patients to determine whether these two
groups were phenotypically distinct. Our results partly confirmed
previous evidence in that ALS-C9Pos patients were younger at
FIGURE 2 | Kaplan-Meier plots of survival probabilities: the patients carrying
the pathogenic C9orf72 repeat expansion (or ALS-C9Pos, red line) display
shorter survival time [median survival of 36 months (95% CI 30–43)] than the
patients without genetic mutations (ALSwoGM, green line) [median survival of
42 months (95% CI 39–45)]. Log-rank χ2 = 3.88, p =.049; +: censored
cases.
onset, at first clinical observation and at diagnosis and exhibited
higher odds of bulbar onset, FTD diagnosis, and family history of
ALS, FTD, and Alzheimer’s disease. Remarkably, we revealed that
ALS-C9Pos patients, especially males, had shorter survival than
ALSwoGM patients, thereby enhancing the emerging hypothesis
that sex may represent a crucial variable in the pathobiology of
C9orf72-mediated disease.
Our findings derived from between-groups comparisons
mirrored previous results regarding lower age at disease
onset (Byrne et al., 2012; Cooper-Knock et al., 2012; Irwin
et al., 2013) and diagnosis (Byrne et al., 2012) in ALS-C9Pos
populations compared to cohorts of non-expanded ALS patients.
Interestingly, the lower age at first observation and diagnosis
described in our cohort of ALS-C9Pos patients was likely due to
the higher attention to appearance of ALS symptoms revealed
in subjects with known family history of ALS, as previously
described in ALS-C9Pos patients (Umoh et al., 2016; Turner
et al., 2017). Additionally, we reported an increased odds of
bulbar onset in ALS-C9Pos patients, as also described in other
cohorts of expanded patients (Chiò et al., 2012; Irwin et al.,
2013; Cooper-Knock et al., 2014). This clinical onset has been
used to identify a more aggressive ALS phenotype, since patients
with bulbar disease may carry a worse prognosis (Magnus et al.,
2002; Chiò et al., 2011) and peculiar neuropsychological and
neuroimaging profiles (Cistaro et al., 2012; Trojsi et al., 2017a),
as also confirmed by our results in which bulbar onset arises
as an independent feature associated to C9orf72 expansion and
negatively impacting on prognostic outcome.
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FIGURE 3 | Kaplan-Meier plots of survival probabilities, stratifying the overall sample by sex: shorter survival time is displayed in ALS-C9Pos patients (red line)
compared to ALSwoGM patients (green line) only for males. (A) (male): Log-rank χ2 = 4.33, p = 0.037; median survival was 35 months (95% CI 26–44) for
ALS-C9Pos (n = 47), and 44 months (95% CI 40–48) for ALSwoGM (n = 681). (B) (female): Log-rank χ2 = 0.43, p = 0.510; median survival was 37 months (95% CI
26–47) for ALS-C9Pos (n = 37), and 42 months (95% CI 37–46) for ALSwoGM (n = 559). +: censored cases.
As expected, we revealed that ALS-C9Pos patients were
more likely to exhibit FTD diagnosis and to report family
history of ALS, FTD, and Alzheimer’s disease, thereby confirming
the previously identified clinical profile of ALS-C9Pos patients
(Byrne et al., 2012, 2013; Chiò et al., 2012; Cooper-Knock et al.,
2012, 2014; Sabatelli et al., 2012; Umoh et al., 2016; Hardiman
et al., 2017). However, we established diagnosis of dementia in
patients’ relatives retrospectively from medical records or from
patients’ reports and this may have underestimated significant
cognitive changes in their pedigrees. Moreover, in the studied
ALS population the formal neuropsychological testing was
performed using heterogeneous protocols among the different
referral centers, without collecting cognitive and behavioral
scores for each patient (Trojsi et al., 2017a).
Of note is also that in our population the C9orf72
expansion was associated with lower odds of spinal onset,
NIV, hypertension, and psychiatric diseases. This evidence
was not unexpected with regard to the lower odds of
association between the C9orf72 expansion and spinal onset
and NIV, in consideration of the above discussed higher odds
of association between the C9orf72 expansion and bulbar
onset, among possible onsets, and given the higher association
between the C9orf72 expansion and dementia, proven to induce
less adherence and compliance to treatments, including NIV
(Govaarts et al., 2016; Mandrioli et al., 2018b).
The association between arterial hypertension and ALS
has been previously investigated, resulting in conflicting
evidence regarding the prognostic role of this comorbidity
(Moreau et al., 2012; Körner et al., 2013; Moglia et al.,
2017; Mandrioli et al., 2018a). In particular, some studies
on large ALS clinic-based cohorts reported conflicting results
on the association between premorbid or comorbid arterial
hypertension and shorter survival in ALS patients (Körner et al.,
2013; Mandrioli et al., 2018a). Probably, our result of a lower
odds of association between C9orf72 expansion and hypertension
may be due to the lack of this comorbidity among clinical
features potentially related to the C9orf72-mediated pathology,
although hypertension was proven associated to shorter survival
time in ALS-C9Pos patients on univariate analysis. To note,
among the potential prognostic factors for survival in ALS,
although we have no information regarding comorbid familial
hypercholesterolemia (FH), 3.14% of ALSwoGM patients and
3.57% of ALS-C9Pos patients had hypercholesterolemia. In
the light of the recent polygenic evidence that low-density
lipoprotein cholesterol (LDL-C) and total cholesterol (TC) are
causally associated with ALS (Chen et al., 2018), large-scale
genome-wide association studies (GWASs) and deep sequencing
for rare variants of LDL-C and TC risk alleles will be needed.
Additionally, the lower odds of association between the
C9orf72 expansion and psychiatric diseases found in our
population, although apparently unexpected, may be explained
on the basis of previous literature referring that behavioral
abnormalities, rather than psychosis or other psychiatric
syndromes per se, within clinical profile of FTD, were frequently
observed among C9orf72 expansion carriers (Watson et al., 2016;
Devenney et al., 2017; Ducharme et al., 2017). Furthermore, as to
the prevalence of neuropsychiatric conditions in relatives of ALS
patients, although psychiatric symptoms have been described
more frequently in ALS kindreds than in non-ALS pedigrees,
the presence of C9orf72 expansion was demonstrated not to fully
account for this association (Byrne et al., 2013), suggesting that
only some subphenotypes of ALS may share pleiotropic genetic
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TABLE 3 | Cox proportional hazards regression multivariate analysis (Forward
Conditional method) performed both in the whole sample and stratified by sex.
Variable B (SE) p-Value HR 95% CI
Whole sample
Step 1
Age at onset 0.04 (0.00) <0.001 1.04 1.03–1.05
Step 2
Age at onset 0.04 (.00) <0.001 1.04 1.03–1.05
Diagnostic delay −0.05 (0.00) <0.001 0.95 0.94–0.96
Step 3
Age at onset 0.04 (0.00) <0.001 1.04 1.03–1.05
Diagnostic delay −0.05 (0.00) <0.001 0.95 0.94–0.96
FTD 0.46 (0.12) <0.001 1.58 1.25–1.99
Step 4
Age at onset 0.03 (0.00) <0.001 1.03 1.03–1.04
Diagnostic delay −0.05 (0.00) <0.001 0.95 0.94–0.96
Site of onset (Bulbar = 0;
Spinal = 1)
−0.25 (0.08) 0.001 0.77 0.66–0.90
FTD 0.42 (0.12) <0.001 1.53 1.21–1.94
Step 5a
Age at onset 0.04 (0.00) <0.001 1.04 1.03–1.05
Diagnostic delay −0.05 (0.00) <0.001 0.95 0.94–0.96
Site of onset (Bulbar = 0;
Spinal = 1)
−0.25 (0.08) 0.002 0.78 0.66–0.91
FTD 0.38 (0.12) 0.002 1.47 1.16–1.86
Family history of ALS 0.31 (0.14) 0.037 1.35 1.01–1.79
Males
Step 1
Diagnostic delay −0.05 (0.00) <0.001 0.95 0.94–0.96
Step 2
Diagnostic delay −0.06 (0.00) <0.001 0.95 0.93–0.96
Age at clinical observation 0.04 (0.00) <0.001 1.04 1.03–1.05
Step 3
Diagnostic delay −0.06 (0.00) <0.001 0.95 0.93–0.96
Age at clinical observation 0.04 (0.00) <0.001 1.03 1.02–1.05
Site of onset (Bulbar = 0;
Spinal = 1)
−0.32 (0.12) 0.005 0.72 0.58–0.91
Step 4b
Diagnostic delay −0.06 (0.00) <0.001 0.95 0.93–0.96
Age at clinical observation 0.04 (0.00) <0.001 1.04 1.03–1.05
Site of onset (Bulbar = 0;
Spinal = 1)
−0.31 (0.12) 0.008 0.73 0.58–0.92
C9orf72 expansion status
(No = 0; SI = 1)
0.46 (0.20) 0.021 1.58 1.07–2.33
Females
Step 1
Age at onset 0.04 (0.00) <0.001 1.04 1.03–1.05
Step 2
Age at onset 0.04 (0.00) <0.001 1.04 1.03–1.05
Diagnostic delay −0.05 (0.00) <0.001 0.95 0.94–0.96
Step 3c
Age at onset 0.04 (0.00) <0.001 1.04 1.03–1.05
Diagnostic delay −05 (0.00) <0.001 0.95 0.94–0.96
FTD 0.65 (0.18) <0.001 1.91 1.33–2.73
SE, Standard Error; HR, Hazard Ratio; CI, Confidence Interval; FTD, frontotemporal
dementia; aVariables not in equation at last step: age at diagnosis, age at
clinical observation, hypertension, psychiatric diseases, and C9orf72 expansion status;
bVariables not in equation at last step: age at diagnosis, age at onset, FTD, hypertension,
psychiatric diseases, and family history of ALS; cVariables not in equation at last step: age
at diagnosis, age at clinical observation, site of onset, hypertension, psychiatric diseases,
family history of ALS, and C9orf72 expansion status.
FIGURE 4 | Hazard plot representing the risk of death/tracheotomy for males
carrying the pathogenic C9orf72 repeat expansion (or ALS-C9Pos, red line)
compared to males without genetic mutations (or ALSwoGM, green line):
shorter survival time is associated with the presence of C9orf72 repeat
expansion (HR 1.58, 95% CI 1.07–2.33, p = 0.021).
risk with neuropsychiatric illnesses (O’Brien et al., 2017). Finally,
there is some evidence that intermediate C9orf72 repeat lengths
are associated with personal or family history of FTD and/or
psychiatric illness, although the “critical” C9orf72 repeat size
required for initiation of neurodegeneration remains unknown
(Ng and Tan, 2017).
Our findings regarding the reduced overall survival in the
ALS-C9Pos population compared to ALSwoGM patients and
the significant associations between some clinical variables and
shorter survival time in ALS-C9Pos patients are consistent,
respectively, with previous evidence from other ALS-C9Pos
cohorts compared to non-expanded ALS cohorts (Byrne et al.,
2012; Chiò et al., 2012; Cooper-Knock et al., 2012; Irwin et al.,
2013; Umoh et al., 2016; Hardiman et al., 2017; Rooney et al.,
2017; Trojsi et al., 2017b) and from sporadic patients (Chiò
et al., 2009; Watanabe et al., 2015). Interestingly, the multivariate
analysis showed that shorter survival time was associated with the
presence of C9orf72 expansion in men when stratifying our ALS
population by sex, thereby pointing toward the hypothesis that
the male sex may drive the effect of the C9orf72 repeat expansion
rather than other prognostic factors, such as dementia and the
clinical phenotype per se. To note, considering that the male sex
could be more prone to certain clinical pathologies that decrease
survival than the female one, to explore the differences in survival
time between men and women, we performed a preliminary
Kaplan-Meier analysis that did not show significant differences in
the survival time betweenmen and women for the overall sample,
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regardless of the stratification due to the presence of C9orf72
repeat expansion (Supplemental Figure 1).
The result of our multivariate analysis, showing a shorter
survival time in men carrying the C9orf72 expansion, resembles
what recently revealed in a combined analysis of the prognostic
characteristics of the C9orf72 repeat expansion, performed in
4925 ALS cases from Dutch, Irish, and Italian population-
based national registers and from two (Belgian and UK) clinical
research center cohorts (Rooney et al., 2017). In this study,
Rooney et al. revealed a previously unrecognized interaction
between the expanded variant and male patients with spinal
onset disease who exhibited a shorter survival (Rooney et al.,
2017). In comparison to our results on survival, the findings by
Rooney et al. (2017) were derived from a more powered analysis,
adequately sound to highlight interactions between the presence
of C9orf72 expansion and more demographic features, such as
sex and site of onset. However, male sex emerges from both
studies as a crucial interacting factor in the biology of C9orf72-
mediated disease, in contrast to previous analyses performed in
non-expanded ALS cohorts, that reported that female sex was an
independent predictor of faster functional decline (Chiò et al.,
2012; Watanabe et al., 2015). Nevertheless, the pathobiology of
the observed interactions between both C9orf72- positive and -
negative variants and sex remains still unclear. In this regard,
the role of environmental risk factors should be emphasized,
as underlined by a recent long-term population-based analysis
from the Piemonte and Valle d’Aosta Register for ALS (PARALS),
that showed that incidence of ALS increased in the last two
decades, mostly in women. A probable explanation for this was
derived from a birth cohort effect in women, who profoundly
modified their lifestyle mainly from 1920, thereby being more
exposed to possible environmental risk factors for ALS (i.e.,
physical activity and cigarette smoking) (Chiò et al., 2017).
These results all together pointed to the potential pathogenic
role of exogenous factors with different gender-effect, probably
derived from interaction with specific genetic backgrounds. In
case ofC9orf72 repeat expansion, several pathogenicmechanisms
have been described, such as haploinsufficiency, toxic RNA
interfering with the function of RNA-binding proteins or other
cellular factors, presence of toxic dipeptide repeat proteins,
and alterations of nucleocytoplasmic transport (Freibaum and
Taylor, 2017). However, the potential interactions between these
mechanisms and environmental risk factors for ALS have not
been elucidated. Finally, the C9orf72 repeat expansion is known
to have an incomplete and age-dependent penetrance and, in
this regard, a recent penetrance model analysis of a large cohort,
drawn from the published literature, reported an older age of
onset among female carriers in general, and among females
with bulbar onset in particular (Murphy et al., 2017), thereby
inducing to hypothesize potential hormonal or X-linked factors
influencing disease type and site of onset.
Limitations of our study were the retrospective nature of
the analysis, causing the unavailability of some data (such as
the neuropsychological scores collected, the specific psychiatric
manifestations, and the C9orf72 repeat size) and the multicenter
design of the study. Moreover, the sample size was relatively
small, thereby implying that our study was not sufficiently
powered to use regression models to explore the effects of known
important survival covariates, including age of onset, site of
onset, diagnostic delay, and C9orf72, and whether the expanded
variant differentially affects outcome in ALS subgroups. In
addition, the genetic panel shared by all participating centers
was initially limited to screening SOD1, C9orf72, TARDBP, and
FUS mutations, and was extended to other ALS- or FTD-related
mutations only in familial cases. Specifically, in the absence
of a family history of ALS, a case-control design, in which
patient samples are compared with samples from people without
ALS, has been recognized as the simplest approach for gene
discovery, although requiring the ability to sequence the whole
genome to identify the rare variation. As low-frequency variation
seems to have a large role in the genetic architecture of ALS,
including apparently sporadic ALS, looking for such variants has
been shown crucial (Al-Chalabi et al., 2017). Increasing efforts
have been made and will be further needed to understand the
genetic component of ALS risk, especially carrying out large-scale
international collaborations for exome analysis or more detailed
genotyping of apparently sporadic patients.
Overall, we underlined that patients with ALS carrying
the C9orf72 repeat expansion exhibit remarkable clinical
and pathological features suggesting that this hexanucleotide
expansion identifies a distinct population of patients. In
particular, the interaction between the C9orf72 repeat expansion
and gender should be further investigated to identify future
disease-related prognostic models with potential, significant
implications for screening of patients, and incorporation into
clinical trials.
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